How some novel combos may be ones to watch out for
Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents
It's time to look to the future beyond plain vanilla ADCs
Important lessons learned from failure
What's next beyond BTK inhibition in lymphomas and CLL?
There is beauty in drugging intractable targets
Spotting the winners and losers in the gastric cancer niche
Some up and coming novel ADCs to watch out for
Eight key areas to watch out for at SITC 2023!
Out of the ashes, a new phoenix can rise
Dawn of a new IO era at ESMO23?
Red and green flags on certain trials at ESMO23
After a long wait, finally some encouraging data in advanced solid tumours!
8 targets to watch out for at ESMO23
What to watch out for in DDR, epigenetic therapies, and other hot topics
From epigenetics to SHP2, a look at various upcoming presentations this month
There's a huge surge in ADCs in the clinic but how many will make an impact?
Parsing cancer research hype at ESMO23
